• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

With MDMA debate spreading beyond biotech, Lykos CEO tries to dispel efficacy, safety concerns

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 13, 2024 at 11:13: AM
via A week after an FDA committee declined to support an midomafetamine (MDMA) treatment for post-traumatic stress disorder (PTSD), Lykos Therapeutics is looking to dispel some concerns about the therapy as the discussion has taken on a life of its own beyond the biotech world.

article source
 

<



Similar threads

cafead
Lykos co-founder Doblin to step down after MDMA setback
Replies
0
Views
17
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Article retractions muddy MDMA waters after FDA denial
Replies
0
Views
18
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Lykos will ask FDA to reconsider its decision following rejection of MDMA therapy for post-traumatic stress disorder
Replies
0
Views
32
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
MDMA therapy is facing an imminent FDA decision. Here’s what you need to know
Replies
0
Views
10
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Lykos’ MDMA-Assisted PTSD Therapy Heads to FDA After Adcomm Setback
Replies
0
Views
16
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote